Abstract: Provided herein are antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain (RBD)), host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain) and methods of using such antibodies to diagnose, prevent or treat a SARS-CoV-2 infection, or COVID-19.

Abstract: Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, N also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering h to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with N (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.

Abstract: PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of promising therapeutic modalities that degrade intracellular protein targets by hijacking the cellular ubiquitin-proteasome system. However, potential toxicity of PROTACs in normal cells due to off-tissue on-target degradation effect limits their clinical applications. Precise control of PROTAC's on-target degradation activity in a tissue selective manner could minimize potential toxicity/side-effects. To this end, we developed a cancer cell selective delivery strategy for PROTACs by conjugating a folate group to ubqiquitin recruitment moiety to achieve targeted degradation of proteins of interest (POIs) in cancer cells versus normal cells. We show that our folate-PROTACs, including BRD PROTAC (Folate-ARV-771), MEK PROTAC (Folate-MS432) and ALK PROTAC (Folate-MS99, Folate-S2-MS4048) are capable of degrading BRDs, MEKs and ALK, respectively, in a folate receptor-dependent manner.

Abstract: Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.

Abstract: Systems and methods are provided for monitoring a user having a chronic gastrointestinal indication. A questionnaire regarding a plurality of conditions is provided on a repeating basis. Each such condition at least partly arises from the gastrointestinal indication. Questionnaire questions are each associated with a corresponding condition and provide an affordance that allows the user to select between low and high values in accordance with user association with the condition. Responses are stored in a data store associated with the user. A user requested report comprising a graphical quality of life measure of the user is provided based upon temporal questionnaire answers. Questionnaire information is communicated to a remote device for medical practitioner evaluation and computation of a temporal overall quality of life score based on a plurality of component quality of life scores, each of which is associated with a condition in the plurality of conditions.

Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.

Abstract: Antibodies and antibody fragments that specifically bind to LILRB3 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB3 and methods of use thereof.

Abstract: The present disclosure provides compositions for and methods of monitoring the progression of and treating gastrointestinal infections in a subject, particularly those involving Clostridioides difficile.

Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotid sequence encoding a SARS-CoV-2 spike protein or nucleocapsid protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.

Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.

Abstract: A method to predict visual field loss includes defining a superior visual field as rows and columns in a coordinate system. The method further includes performing a display and record process for a first column of the columns by: initiating a base condition, initiating a recurrence condition, and initiating a stop condition when a difference between the new pivot point and a previous pivot point is less than a predetermined threshold. The method further includes repeating the display and record process for additional columns of the columns. The method further includes defining an eyelid meridian based on recorded coordinates for a set of points that are visible to the patient, calculating an area of the superior visual field based on the eyelid meridian, and determining the visual field loss based the area of the superior visual field.

Abstract: Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.

Abstract: Systems and methods for three-dimensional dose prediction and treatment planning using a deep learning fully convolutional neural network are disclosed.

Abstract: Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

Abstract: The invention is directed to production of megakaryocyte (MK) compositions and their the treatment of thrombocytopenia in a subject in need thereof.

Abstract: A screening platform enables comprehensive ocular evaluations. The screening platform includes a harness that is configured to fit a head of a patient and that includes one or more electronic components that are operable to power an interchangeable module, a central processing unit (CPU) with a graphical processing unit (GPU), and the interchangeable module with communication capabilities to external computational devices, multiple display output devices, and several types of input devices from both an operator and a patient at-hand, wherein the interchangeable module is separable from the screening platform.

Abstract: Compounds which are oxadiazaborole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

Abstract: An imaging compatible device for applying a plurality of different loads to a foot for evaluating the Lisfranc joint of a patient is configured to move the ball of the foot in an axial direction, a lateral direction, and a torsional direction to assess a state of the Lisfranc joint.

Abstract: In one aspect, provided herein are methods for treating cancer in a subject, comprising administering to a subject an oncolytic virus (e.g., an avian paramyxovirus (AMPV)) and a vascular endothelial growth factor (VEGF)-C agent, a VEGF-D agent, or a VEGF receptor (VEGFR)-3-activating agent. In another aspect, provided herein are oncolytic viruses (e.g. APMV) comprising a genome, wherein the genome comprises a transgene that comprises a nucleotide sequence encoding a VEGF-C agent, a VEGF-D agent or a VEGF receptor (VEGFR)-3-activating agent. In another aspect, provided herein are methods for treating cancer, comprising administering to a subject an oncolytic virus (e.g. APMV), wherein the oncolytic virus comprises a genome that comprises a transgene comprising a nucleotide sequence encoding a VEGF-C agent, a VEGF-D agent, or a VEGF receptor (VEGFR)-3-activating agent.